Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab | Zendy

İrfan Çiçin | Zendy; Alaattin Özen | Zendy; Atakan Sezer | Zendy; Sernaz Uzunoğlu | Zendy; Mert Saynak | Zendy; Hakan Gençhellaç | Zendy; Hakan Karagöl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab

Author(s) -

İrfan Çiçin,

Alaattin Özen,

Atakan Sezer,

Sernaz Uzunoğlu,

Mert Saynak,

Hakan Gençhellaç,

Hakan Karagöl

Publication year - 2009

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.52791

Subject(s) - medicine , bevacizumab , discontinuation , folfiri , thrombosis , colorectal cancer , surgery , side effect (computer science) , adverse effect , cancer , irinotecan , chemotherapy , computer science , programming language

The adverse effects of regimes in cancer treatment have forced us to change to new targeted therapy options. Understanding these side effects, which can lead to discontinuation of the new therapy strategies, will allow the clinical management of these side effects and result in continuing therapies with effective medications. Bevacizumab, which is an IgG1 antibody against vascular endothelial growth factor, has side effects such as proteinuria, hypertension, venous and arterial thromboembolic events, and hemorrhage. This is the first reported case of dural sinus vein thrombosis, during the treatment with bevacizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research